STAT Plus: A preview of Neurocrine’s muscarinic drug readout
Adam’s Biotech Scorecard
Adam’s Biotech Scorecard is a subscriber-only newsletter offering unfiltered analysis from Adam Feuerstein, a veteran reporter with decades of experience covering the intersection of Wall Street and biotechnology. It’s delivered on Thursday mornings, and STAT+ subscribers can sign up here.
Latest
STAT Plus: Novartis not ready to admit a $3 billion mistake
STAT Plus: What’s next for Cassava Sciences, and Cartesian Therapeutics has a novel excuse for dodgy data
STAT Plus: A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals
STAT Plus: Will Geron be acquired? The long-short view
STAT Plus: PDS Biotech’s survival benefit is absurdly overstated
STAT Plus: Cytokinetics set to pitch its heart drug to physicians — and Big Pharma suitors
STAT Plus: Novartis’ $3 billion MorphoSys boondoggle